StatOrigin open statistical archive
Industries Indicators Regions Rankings Reports Compare Sources

First-in-class drug approvals vs Clinical trial country use share in China

In 2023, first-in-class drug approvals in China was 40; clinical trial country use share was 15%.

Change the pair

Compare different indicators

The series

Over time

China, spaced by time in 2023 . Different units, drawn on separate scales and clipped to the years both series publish — earlier history stays on each indicator's own page. Read the values, not the heights.

First-in-class drug approvals

Unit: count · 1 observation

Line chart
First-in-class drug approvalsFirst-in-class drug approvals. 1 observations from 2023 to 2023, ranging from 40 to 40. 0 10 20 30 40 31 Dec 2 Jan 2023 40
First-in-class drug approvalsFirst-in-class drug approvals. 1 observations from 2023 to 2023, ranging from 40 to 40. 0 10 20 30 40 31 Dec 2 Jan 2023 40
First-in-class drug approvalsFirst-in-class drug approvals. 1 observations from 2023 to 2023, ranging from 40 to 40. 0 10 20 30 40 31 Dec 2 Jan 2023 40
View the underlying data
First-in-class drug approvals
Period Type Value
2023 Actual 40
Source: NMPA · CC BY 4.0 · Full series

Clinical trial country use share

Unit: % · 1 observation

Line chart
Clinical trial country use shareClinical trial country use share. 1 observations from 2023 to 2023, ranging from 15% to 15%. % 0 3 6 9 12 15 31 Dec 2 Jan 2023 15%
Clinical trial country use shareClinical trial country use share. 1 observations from 2023 to 2023, ranging from 15% to 15%. % 0 5 10 15 31 Dec 2 Jan 2023 15%
Clinical trial country use shareClinical trial country use share. 1 observations from 2023 to 2023, ranging from 15% to 15%. % 0 5 10 15 31 Dec 2 Jan 2023 15%
View the underlying data
Clinical trial country use share
Period Type Value
2023 Actual 15%
Source: IQVIA · CC BY 4.0 · Full series

Shared periods

Side by side

Only one period is published for both series in China. Comparing anything else would mean comparing different years.

Period First-in-class drug approvals Clinical trial country use share
2023 40 15%

Provenance

Where these numbers come from

First-in-class drug approvals

Number of approved therapeutic drugs featuring a novel biological mechanism of action.

4 observations in China · source organisations: NMPA, NHSA

Clinical trial country use share

Percentage of total clinical trial country uses accounted for by a given region.

3 observations in China · source organisations: IQVIA

Data published under CC BY 4.0. Series A as JSON · Series B as JSON

Keep exploring

Related

The two series

Go further